{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:02:10Z","timestamp":1790694130543,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative 2 Joint Undertaking","doi-asserted-by":"publisher","award":["853989"],"award-info":[{"award-number":["853989"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008890","name":"University of Dundee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.isci.2026.115292","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:00:03Z","timestamp":1773162003000},"page":"115292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["An assay toolkit for anti-tuberculosis drugs in the hollow fiber system"],"prefix":"10.1016","volume":"29","author":[{"given":"Fernando","family":"Sanz-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Ndjogou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Aguilar-Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime R.","family":"Eveque-Mourroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ben\u00edtez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Isach-Traver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Mendoza-Losana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Willand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Luc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ram\u00f3n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115292_bib1","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115292_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/civ484","article-title":"Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience","volume":"61","author":"Cavaleri","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115292_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkp434","article-title":"In vitro pharmacodynamic models to determine the effect of antibacterial drugs","volume":"65","author":"Gloede","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10121515","article-title":"Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model","volume":"10","author":"Maitra","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.isci.2026.115292_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2017.09.011","article-title":"Pre-clinical in vitro infection models","volume":"36","author":"Drusano","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib8","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/jac\/dkab160","article-title":"Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting","volume":"76","author":"Sadouki","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/978-1-0716-1460-0_31","article-title":"Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor","volume":"2314","author":"Mason","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.isci.2026.115292_bib10","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/cid\/civ427","article-title":"Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115292_bib11","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiu610","article-title":"Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia","volume":"211","author":"Gumbo","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115292_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49556-5","article-title":"Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection","volume":"9","author":"Kloprogge","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.115292_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics13121201","article-title":"Dynamic In Vitro PK\/PD Infection Models for the Development and Optimisation of Antimicrobial Regimens: A Narrative Review","volume":"13","author":"Wale","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.isci.2026.115292_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijantimicag.2018.10.012","article-title":"Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation","volume":"53","author":"Heinrichs","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.isci.2026.115292_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01080-23","article-title":"Omadacycline pharmacokinetics\/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model","volume":"68","author":"Singh","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106968","article-title":"Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen","volume":"62","author":"Singh","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.isci.2026.115292_bib17","doi-asserted-by":"crossref","first-page":"e02039-16","DOI":"10.1128\/AAC.02039-16","article-title":"Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing","volume":"61","author":"van Rijn","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib18","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115292_bib19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/jac\/dkz460","article-title":"Duration of pretomanid\/moxifloxacin\/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics","volume":"75","author":"Srivastava","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib20","article-title":"Novel tuberculosis combination regimens of two and three-months therapy duration","author":"Gumbo","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.isci.2026.115292_bib21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.mib.2013.06.010","article-title":"PK\/PD models in antibacterial development","volume":"16","author":"Velkov","year":"2013","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.isci.2026.115292_bib22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/bcp.16068","article-title":"Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin","volume":"90","author":"Aguilar-Ayala","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib23","unstructured":"Hollow Fiber System of Tuberculosis (HFS-TB): A Laboratory Manual to Guide System Engineering, Study Design and Execution. (2018). 1-30."},{"key":"10.1016\/j.isci.2026.115292_bib24","series-title":"Concepts and Experimental Protocols of Modelling and Informatics in Drug Design","first-page":"299","article-title":"ADMET tools: Prediction and assessment of chemical ADMET properties of NCEs","author":"Silakari","year":"2021"},{"key":"10.1016\/j.isci.2026.115292_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.isci.2026.115292_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114066","article-title":"Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance","volume":"229","author":"Perveen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.isci.2026.115292_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01612-2016","article-title":"Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis","volume":"49","author":"Van der Paardt","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.isci.2026.115292_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115292_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17512433.2017.1366311","article-title":"Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?","volume":"10","author":"Alfarisi","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01464-24","article-title":"Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system","volume":"69","author":"Raaijmakers","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib59","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"van Heeswijk","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib60","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/jac\/dkaa550","article-title":"Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis","volume":"76","author":"Alghamdi","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib61","doi-asserted-by":"crossref","first-page":"716","DOI":"10.5588\/ijtld.21.0022","article-title":"Bedaquiline for multidrug-resistant TB in paediatric patients","volume":"25","author":"Moodliar","year":"2021","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.isci.2026.115292_bib62","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/psp4.12147","article-title":"Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin","volume":"5","author":"Svensson","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib63","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1152\/jappl.1996.80.6.1911","article-title":"Volume and protein concentration of epithelial lining liquid in perfused in situ postnatal sheep lungs","volume":"80","author":"Stephens","year":"1996","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.isci.2026.115292_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02399-20","article-title":"Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis","volume":"65","author":"Ngwalero","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib65","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0149-2918(01)80060-6","article-title":"Pharmacokinetics and tolerability of extended-release clarithromycin","volume":"23","author":"Guay","year":"2001","journal-title":"Clin. Ther."},{"key":"10.1016\/j.isci.2026.115292_bib66","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s13346-020-00851-z","article-title":"Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration. Drug","volume":"11","author":"Ramirez","year":"2021","journal-title":"Deliv. Transl. Res."},{"key":"10.1016\/j.isci.2026.115292_bib33","unstructured":"TB-platform for the Aggregation of Preclinical Experiments Data (TB-APEX). (2024) https:\/\/c-path.org\/tools-platforms\/tb-apex\/TB-Platform."},{"key":"10.1016\/j.isci.2026.115292_bib67","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/AAC.02600-15","article-title":"Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines","volume":"60","author":"Bekker","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib68","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/jac\/dkac127","article-title":"Population pharmacokinetics of ethambutol in African children: a pooled analysis","volume":"77","author":"Tikiso","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib69","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF01059382","article-title":"Disposition kinetics of ethambutol in man","volume":"8","author":"Lee","year":"1980","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.isci.2026.115292_bib70","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/651377","article-title":"Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol","volume":"201","author":"Srivastava","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115292_bib71","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1128\/AAC.49.2.853-856.2005","article-title":"Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system","volume":"49","author":"Ginsburg","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib72","series-title":"The quinolones, 3rd ed.","first-page":"169","article-title":"Pharmacodynamics and pharmacokinetics of the fluoroquinolones","author":"Kim","year":"2000"},{"key":"10.1016\/j.isci.2026.115292_bib73","doi-asserted-by":"crossref","first-page":"e02359-17","DOI":"10.1128\/AAC.02359-17","article-title":"Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients","volume":"62","author":"Lyons","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib74","article-title":"Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study","volume":"73\u201374","author":"Liu","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.115292_bib75","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40262-023-01217-7","article-title":"Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling","volume":"62","author":"Mehta","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.isci.2026.115292_bib76","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/bcp.70163","article-title":"Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically-based pharmacokinetic modelling","volume":"91","author":"Karakitsios","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib77","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bcp.15925","article-title":"Model-based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug-resistant tuberculosis","volume":"90","author":"Mehta","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00139-10","article-title":"The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model","volume":"1","author":"Drusano","year":"2010","journal-title":"mBio"},{"key":"10.1016\/j.isci.2026.115292_bib78","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib79","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00228-014-1798-3","article-title":"A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example","volume":"71","author":"Clewe","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib30","article-title":"Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis","volume":"14","author":"Deshkar","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.isci.2026.115292_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.medmal.2016.04.007","article-title":"In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M","volume":"46","author":"Lounis","year":"2016","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.isci.2026.115292_bib34","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dkad029","article-title":"Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development","volume":"78","author":"Gumbo","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib35","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00228-014-1740-8","article-title":"Between-subject variability: should high be the new normal?","volume":"70","author":"Al-Sallami","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib37","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/ciw473","article-title":"Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115292_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071485","article-title":"The Application of Hollow Fiber Cartridge in Biomedicine","volume":"14","author":"Hou","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.isci.2026.115292_bib39","doi-asserted-by":"crossref","unstructured":"ACS. Exploring QSAR: Fundamentals and Applications in Chemistry and Biology. Am. Chem. Soc. 1995;39:1189\u20131190. doi:10.1021\/jm950902o.","DOI":"10.1021\/jm950902o"},{"key":"10.1016\/j.isci.2026.115292_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102289","article-title":"Isoniazid pharmacokinetics\/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii","volume":"138","author":"Boorgula","year":"2023","journal-title":"Tuberculosis"},{"key":"10.1016\/j.isci.2026.115292_bib41","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e104","article-title":"Application of the Hollow-Fiber Infection Model to Personalized Precision Dosing of Isoniazid in a Clinical Setting","volume":"39","author":"Park","year":"2024","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.isci.2026.115292_bib42","doi-asserted-by":"crossref","first-page":"9131","DOI":"10.1039\/c2jm30695f","article-title":"Hydrophilic poly(vinylidene fluoride) (PVDF) membrane by in situ polymerisation of 2-hydroxyethyl methacrylate (HEMA) and micro-phase separation","volume":"22","author":"Tao","year":"2012","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.isci.2026.115292_bib43","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1021\/acs.chemrev.2c00477","article-title":"Cellulose: A Review of Water Interactions, Applications in Composites, and Water Treatment","volume":"123","author":"Etale","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.isci.2026.115292_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.surfcoat.2016.12.059","article-title":"Polyethylene glycol coating for hydrophilicity enhancement of polydimethylsiloxane self-driven microfluidic chip","volume":"320","author":"Long","year":"2017","journal-title":"Surf. Coat. Technol."},{"key":"10.1016\/j.isci.2026.115292_bib45","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1080\/19443994.2015.1081628","article-title":"Enhancing hydrophilicity performance of polysulfone hollow fiber membrane by surface modification via UV-induced graft polymerization of HEA","volume":"57","author":"Wang","year":"2016","journal-title":"Desalination Water Treat."},{"key":"10.1016\/j.isci.2026.115292_bib46","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/pi.5401","article-title":"Enhanced hydrophilic polysulfone hollow fiber membranes with addition of iron oxide nanoparticles","volume":"66","author":"Said","year":"2017","journal-title":"Polym. Int."},{"key":"10.1016\/j.isci.2026.115292_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jece.2021.105873","article-title":"High flux polysulfone braided hollow fiber membrane for wastewater treatment role of zinc oxide as hydrophilic enhancer","volume":"9","author":"Peechmani","year":"2021","journal-title":"J. Environ. Chem. Eng."},{"key":"10.1016\/j.isci.2026.115292_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.memsci.2018.04.044","article-title":"A method for coating of hollow fiber membranes with calcium alginate","volume":"558","author":"Yoo","year":"2018","journal-title":"J. Memb. Sci."},{"key":"10.1016\/j.isci.2026.115292_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1100488","article-title":"Clofazimine for the treatment of tuberculosis","volume":"14","author":"Stadler","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.115292_bib50","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","article-title":"Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis","volume":"48","author":"Jayaram","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib51","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib52","doi-asserted-by":"crossref","first-page":"e01207-20","DOI":"10.1128\/AAC.01207-20","article-title":"Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis","volume":"65","author":"Mallikaarjun","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics10121559","article-title":"Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study","volume":"10","author":"Beraldi-Magalhaes","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.isci.2026.115292_bib54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00849-10","article-title":"PA-824 exhibits time-dependent activity in a murine model of tuberculosis","volume":"55","author":"Ahmad","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib55","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/jac\/dkac070","article-title":"Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid","volume":"77","author":"Bateson","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib56","first-page":"1","article-title":"The Hollow Fiber Infection Model: Principles and Practice","volume":"1","author":"Cadwell","year":"2015","journal-title":"Adv Antibiotics Antibodies"},{"key":"10.1016\/j.isci.2026.115292_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1056\/NEJMc2103049","article-title":"Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations","volume":"386","author":"Omar","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115292_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00946-25","article-title":"Pharmacokinetic\/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producing Klebsiella pneumoniae isolates in a hollow-fiber infection model","volume":"69","author":"Rodr\u00edguez-Ochoa","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.isci.2026.115292_bib80","unstructured":"European Medicines Agency. Investigation of Bioequivalence - Scientific Guideline. Available online. (2010)."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422600667X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258900422600667X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:37:59Z","timestamp":1790692679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258900422600667X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S258900422600667X"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115292","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An assay toolkit for anti-tuberculosis drugs in the hollow fiber system","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115292"}}